Immatics Updates IMA203CD8 Clinical Data, Shows Anti-Tumor Activity
Immatics announced updated Phase 1a dose escalation data from its second-generation PRAME cell therapy, IMA203CD8, in heavily pre-treated patients with solid tumors. Based on the enhanced pharmacology of IMA203CD8 reported previously, IMA203CD8 provides the potential to address difficult-to-treat solid tumors expressing PRAME beyond melanoma, such as ovarian cancer. The data from the ongoing Phase 1a trial will be presented at the European Society for Medical Oncology Immuno-Oncology Congress 2025 during a Mini Oral Presentation by Prof. Dr. med. Antonia Busse, Charite, Berlin, Germany. Patient Population: Heavily pre-treated patient population with limited treatment options: As of the data cutoff on October 27, 2025, 781 heavily pre-treated patients with advanced and/or metastatic solid tumors expressing PRAME were enrolled in the ongoing Phase 1a dose escalation clinical trial. The median total infused dose across seven escalating dose levels was 1.6x109 TCR T cells. The efficacy-evaluable patient population included 69 patients: 42 with melanoma, 11 with ovarian carcinoma, 11 with synovial sarcoma and 5 with other tumor types. Safety: Treatment with IMA203CD8 showed manageable tolerability: IMA203CD8 showed manageable tolerability in the 78 patients enrolled. The most frequent treatment-emergent adverse events were anticipated cytopenias associated with lymphodepletion. Expected and manageable cytokine release syndrome was mostly Grade 1 to 2 and was consistent with the mechanism of action: Grade 1: 35%, Grade 2: 50%, Grade 3: 9%, Grade 4: 1%. Immune effector cell-associated neurotoxicity syndrome and hemophagocytic lymphohistiocytosis were infrequently observed. No IMA203CD8-related Grade 5 events occurred. Based on the manageable tolerability profile, dose escalation is ongoing at dose level 7 and on track to determine the recommended Phase 2 dose. Anti-tumor Activity and Durability: Deep and durable objective responses in PRAME-positive advanced solid tumors during ongoing dose escalation. A one-time infusion of IMA203CD8 PRAME cell therapy showed promising initial anti-tumor activity during dose escalation across various PRAME-expressing indications at a low median dose of 1.6x109 total IMA203CD8 TCR T cells: Confirmed Objective Response Rate: 36%; Objective Response Rate: 46%; Tumor reduction: 78%; Disease Control Rate at week 6: 84%; Median Duration of Response: 9.2 months at a median follow-up of 14 months. Deep and durable objective responses were observed for up to 3+ years. The data also showed three complete responses in addition to two confirmed partial responses with -100% reduction of target lesions across indications. 66% of responders exhibited deep responses with tumor reduction of greater than or equal to 50%, and seven responses remained ongoing for greater than or equal to 1 year post infusion. In patients with ovarian carcinoma, a promising, dose-dependent signal was observed, including deep, confirmed objective responses at higher dose levels. Among the five patients with ovarian carcinoma treated with IMA203CD8 at greater than or equal toDL5, two confirmed partial responses were observed, one of which is an ongoing metabolic complete response in the patient treated at the highest dose in the ovarian carcinoma efficacy population to date, and an additional unconfirmed PR. All responders were resistant to previous platinum-based chemotherapy. All responses were observed in patients who did not receive post-infusion low-dose IL-2. In addition, tolerability in ovarian carcinoma was generally consistent with the full IMA203CD8 tolerability profile. Within Immatics' PRAME franchise, its lead PRAME cell therapy, anzu-cel, showed a cORR of 19% during dose escalation. With enhanced pharmacology, IMA203CD8 is designed to build on the potential of anzu-cel in additional tumor types across a broad spectrum of PRAME expression levels and characterized by a more complex tumor microenvironment than melanoma, such as ovarian carcinoma. Immatics aims to position IMA203CD8 in the tumor-agnostic setting of advanced PRAME cancers beyond melanoma, starting with gynecologic cancers. In addition, the Phase 1 trial could support the positioning of IMA203CD8 without the requirement of post-infusion low-dose IL-2 in the future. The Company believes the early proof-of-concept data in ovarian carcinoma presented today support this strategy. The Company is on track to complete Phase 1a dose escalation and determine RP2D in 2026, including data on the two highest dose levels, to unlock the full clinical potential of IMA203CD8.
Trade with 70% Backtested Accuracy
Analyst Views on IMTX
About IMTX
About the author
Immatics Sells 12.5M Shares at $10 Each, Raising $125M
- Funding Scale: Immatics has announced the sale of 12,500,000 ordinary shares at $10 each, expected to raise $125 million, which will provide crucial funding for the company's clinical development initiatives.
- Underwriter Lineup: The offering is being managed by Jefferies, Leerink Partners, and Cantor, reflecting market confidence in Immatics' future growth and potentially enhancing its reputation in the biopharmaceutical sector.
- Transaction Timeline: The offering is expected to close on December 8, 2025, subject to customary closing conditions, allowing the company to quickly access funds to support its research projects.
- Market Reaction Expectations: This financing will bolster Immatics' research capabilities in precision targeting of PRAME, potentially enhancing its competitive position in cancer treatment, particularly in therapies targeting over 50 types of cancer.
Xilio Therapeutics, Inc. (XLO) Announces Q3 Loss and Falls Short of Revenue Projections
Quarterly Performance: Xilio Therapeutics reported a quarterly loss of $0.03 per share, matching expectations, and significantly improved from a loss of $0.22 per share a year ago, while revenues of $19.07 million fell short of estimates by 28.51%.
Stock Outlook: The company's shares have declined by 19% this year, contrasting with the S&P 500's 16.5% gain, and the stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Earnings Estimates: The consensus EPS estimate for the upcoming quarter is -$0.12 on revenues of $7.96 million, with a fiscal year estimate of -$0.45 on $45.65 million in revenues, reflecting mixed trends in earnings estimate revisions.
Industry Context: Xilio operates within the Medical - Biomedical and Genetics industry, which ranks in the top 35% of Zacks industries, suggesting that industry performance could significantly influence the stock's future.
Immatics Showcases Promising Anti-Tumor Effects of Anzu-cel PRAME Cell Therapy for Metastatic Uveal Melanoma at ESMO 2025 Presidential Symposium
Clinical Trial Results: An ongoing Phase 1b trial of anzu-cel (PRAME cell therapy) in 16 patients with metastatic uveal melanoma shows a confirmed objective response rate of 67%, with a median duration of response of 11 months and median progression-free survival of 8.5 months.
Safety and Tolerability: Anzu-cel demonstrates a favorable tolerability profile, with manageable treatment-emergent adverse events primarily related to cytopenias and cytokine release syndrome, indicating its potential as a treatment option for this difficult-to-treat cancer.
Future Development: Due to the promising results, Immatics has initiated a Phase 2 cohort study for anzu-cel in metastatic uveal melanoma, aiming to expand its application in this area of high unmet medical need.
Company Overview: Immatics is a clinical-stage biopharmaceutical company focused on precision targeting of PRAME, with a robust pipeline of therapies aimed at various cancers, including ongoing trials for both uveal and cutaneous melanoma.
Immatics Names Venkat Ramanan as Chief Financial Officer
New CFO Appointment: Immatics N.V. has appointed Venkat Ramanan as Chief Financial Officer, effective immediately, succeeding Arnd Christ.
Ramanan's Background: Venkat Ramanan brings over 25 years of experience in the biopharmaceutical industry, having previously served as CFO at Anthos Therapeutics, a Novartis company.
Stock Performance: Following the announcement, Immatics' stock closed 7.71% higher at $8.52 on the Nasdaq.
Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
Immatics Names Venkat Ramanan as CFO
New CFO Appointment: Immatics N.V. has appointed Venkat Ramanan, Ph.D., as Chief Financial Officer, effective immediately, succeeding Arnd Christ. Dr. Ramanan brings over 25 years of experience in the biopharmaceutical industry, having held leadership roles at companies like Seagen, Gilead Sciences, and Amgen.
Focus on PRAME Cell Therapy: Dr. Ramanan's expertise will support Immatics in advancing its PRAME cell therapy, anzu-cel, towards commercialization, particularly for patients with metastatic melanoma, as the company aims to strengthen its position as a leader in precision targeting of PRAME.
Guggenheim Begins Coverage of Immatics N.V. (IMTX) with a Buy Rating
Guggenheim Coverage Initiation: Guggenheim initiated coverage of Immatics N.V. with a "Buy" recommendation on September 18, 2025, projecting a 113.83% upside based on an average one-year price target of $14.13/share.
Institutional Ownership Trends: There are currently 109 funds reporting positions in Immatics N.V., with a 14.17% decrease in owners over the last quarter, while total shares owned by institutions increased by 1.26% to 98,918K shares.
Significant Shareholder Increases: Major shareholders like T. Rowe Price, Suvretta Capital, and Baker Bros. Advisors have significantly increased their holdings in Immatics N.V. over the last quarter, with increases ranging from 19.92% to 46.16%.
Bullish Market Sentiment: The put/call ratio for IMTX is 0.19, indicating a bullish outlook among investors, despite a decrease in the number of funds holding shares.
Immatics Sells 12.5M Shares at $10 Each, Raising $125M
- Funding Scale: Immatics has announced the sale of 12,500,000 ordinary shares at $10 each, expected to raise $125 million, which will provide crucial funding for the company's clinical development initiatives.
- Underwriter Lineup: The offering is being managed by Jefferies, Leerink Partners, and Cantor, reflecting market confidence in Immatics' future growth and potentially enhancing its reputation in the biopharmaceutical sector.
- Transaction Timeline: The offering is expected to close on December 8, 2025, subject to customary closing conditions, allowing the company to quickly access funds to support its research projects.
- Market Reaction Expectations: This financing will bolster Immatics' research capabilities in precision targeting of PRAME, potentially enhancing its competitive position in cancer treatment, particularly in therapies targeting over 50 types of cancer.
Xilio Therapeutics, Inc. (XLO) Announces Q3 Loss and Falls Short of Revenue Projections
Quarterly Performance: Xilio Therapeutics reported a quarterly loss of $0.03 per share, matching expectations, and significantly improved from a loss of $0.22 per share a year ago, while revenues of $19.07 million fell short of estimates by 28.51%.
Stock Outlook: The company's shares have declined by 19% this year, contrasting with the S&P 500's 16.5% gain, and the stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Earnings Estimates: The consensus EPS estimate for the upcoming quarter is -$0.12 on revenues of $7.96 million, with a fiscal year estimate of -$0.45 on $45.65 million in revenues, reflecting mixed trends in earnings estimate revisions.
Industry Context: Xilio operates within the Medical - Biomedical and Genetics industry, which ranks in the top 35% of Zacks industries, suggesting that industry performance could significantly influence the stock's future.
Immatics Showcases Promising Anti-Tumor Effects of Anzu-cel PRAME Cell Therapy for Metastatic Uveal Melanoma at ESMO 2025 Presidential Symposium
Clinical Trial Results: An ongoing Phase 1b trial of anzu-cel (PRAME cell therapy) in 16 patients with metastatic uveal melanoma shows a confirmed objective response rate of 67%, with a median duration of response of 11 months and median progression-free survival of 8.5 months.
Safety and Tolerability: Anzu-cel demonstrates a favorable tolerability profile, with manageable treatment-emergent adverse events primarily related to cytopenias and cytokine release syndrome, indicating its potential as a treatment option for this difficult-to-treat cancer.
Future Development: Due to the promising results, Immatics has initiated a Phase 2 cohort study for anzu-cel in metastatic uveal melanoma, aiming to expand its application in this area of high unmet medical need.
Company Overview: Immatics is a clinical-stage biopharmaceutical company focused on precision targeting of PRAME, with a robust pipeline of therapies aimed at various cancers, including ongoing trials for both uveal and cutaneous melanoma.
Immatics Names Venkat Ramanan as Chief Financial Officer
New CFO Appointment: Immatics N.V. has appointed Venkat Ramanan as Chief Financial Officer, effective immediately, succeeding Arnd Christ.
Ramanan's Background: Venkat Ramanan brings over 25 years of experience in the biopharmaceutical industry, having previously served as CFO at Anthos Therapeutics, a Novartis company.
Stock Performance: Following the announcement, Immatics' stock closed 7.71% higher at $8.52 on the Nasdaq.
Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
Immatics Names Venkat Ramanan as CFO
New CFO Appointment: Immatics N.V. has appointed Venkat Ramanan, Ph.D., as Chief Financial Officer, effective immediately, succeeding Arnd Christ. Dr. Ramanan brings over 25 years of experience in the biopharmaceutical industry, having held leadership roles at companies like Seagen, Gilead Sciences, and Amgen.
Focus on PRAME Cell Therapy: Dr. Ramanan's expertise will support Immatics in advancing its PRAME cell therapy, anzu-cel, towards commercialization, particularly for patients with metastatic melanoma, as the company aims to strengthen its position as a leader in precision targeting of PRAME.
Guggenheim Begins Coverage of Immatics N.V. (IMTX) with a Buy Rating
Guggenheim Coverage Initiation: Guggenheim initiated coverage of Immatics N.V. with a "Buy" recommendation on September 18, 2025, projecting a 113.83% upside based on an average one-year price target of $14.13/share.
Institutional Ownership Trends: There are currently 109 funds reporting positions in Immatics N.V., with a 14.17% decrease in owners over the last quarter, while total shares owned by institutions increased by 1.26% to 98,918K shares.
Significant Shareholder Increases: Major shareholders like T. Rowe Price, Suvretta Capital, and Baker Bros. Advisors have significantly increased their holdings in Immatics N.V. over the last quarter, with increases ranging from 19.92% to 46.16%.
Bullish Market Sentiment: The put/call ratio for IMTX is 0.19, indicating a bullish outlook among investors, despite a decrease in the number of funds holding shares.
